Premium
Influence of statin‐potency on the risk of kidney disease – A nationwide cohort study using laboratory data
Author(s) -
Citarella Anna,
Linder Marie,
Cammarota Simona,
Sundström Anders,
Kieler Helle
Publication year - 2021
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.5173
Subject(s) - medicine , potency , statin , kidney disease , hazard ratio , renal function , proportional hazards model , cohort , pharmacoepidemiology , pharmacology , confidence interval , medical prescription , biochemistry , chemistry , in vitro
Purpose To estimate the risk of kidney disease in high‐potency statin users compared to those treated with low‐potency statins without history of kidney disease at statin initiation, linking the Swedish national healthcare registers and laboratory data. Methods Incident users of statins, ≥40 years of age, with estimated Glomerular Filtration Rate (eGFR) >60 ml/min/1.73 m 2 and no diagnosis of kidney disease at treatment initiation were identified between 2006 and 2007 and then followed for 2‐years. The outcome was the incidence of kidney disease identified by the presence of the diagnostic code in the healthcare registers or eGFR <60 ml/min/1.73 m 2 . We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) with adjusted and propensity score (PS)‐matched Cox proportional hazards models. Results A total of 27 385 patients were identified, 25.2% of which treated with a high‐potency statin. During the follow‐up, 68 (0.25%) patients were identified with a diagnosis of kidney disease from the registers. The number increased to 2498 (9.1%) when the criteria of eGFR <60 ml/min/1.73 m 2 was added. The adjusted HR of kidney disease in high‐potency statin users was 1.14 (95%CI 1.03–1.25) compared to low‐potency users; the result was unchanged after the PS approach. Conclusions Adding information from laboratory data to those from the national health registers, a slightly increased risk for kidney disease was found in high‐potency statin users without pre‐existing kidney disease at treatment initiation compared to those treated with low‐potency statins.